[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,97,0,25,[9,51,82,109,138,156,184,207,264,289,314,338,370,393,416,441,462,483,509,532,557,582,605,629,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100644592","integrating-systematic-patient-reported-evaluations-in-multi-disciplinary-tumor-boards-the-inspire-study-100644592",false,"NCT07671937","INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study","INSPIRE","Inclusion\u002FExclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB.\n\nInclusion Criteria:\n\n* Inclusions Criteria- Patients:\n\n  1. aged 18 years or older;\n  2. with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;\n  3. intention to be treated at a participating institution;\n  4. with verbal fluency in English or Spanish; and\n  5. scheduled to be discussed at MDTB.\n* Inclusion criteria - Clinicians:\n\nAll clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.\n\nExclusion Criteria:\n\n* Exclusion criteria - Patients:\n\nIndividuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish.\n\n* Exclusion criteria - Clinician:\n\nClinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.","ALL","18 Years",{"count":20,"type":21},2748,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.",[27,28,29,30,31],"Breast Cancer","Corpus Uteri Cancer","Ovary Cancer","Pancreas Cancer","Other Female Genital Malignant Neoplasms",[33,34,35,36,27,37],"PROs","Multidiscipinary tumor board","INSPIRE intervention","Pancreatic Cancer","gynecologic cancers","NOT_YET_RECRUITING","2026-06-30",{"date":41,"type":42},"2026-07-02","ACTUAL",{"date":44,"type":21},"2026-09-01",{"date":46,"type":21},"2031-07",{"name":48,"class":49},"University of Alabama at Birmingham","OTHER",3,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100594635","predictive-risk-factors-for-pancreatic-fistula-after-pancreaticoduodenectomy-100594635","NCT07022015","Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy","Predictive Risk Factors for Postoperative Pancreatic Fistula After Pancreaticoduodenectomy for Malignancy.","POPF","Inclusion Criteria:\n\n* Patients with resectable distal common bile duct carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas.\n* Patients meeting the curative treatment intent in accordance with clinical guidelines:\n\n  * No evidence of metastasis.\n  * Radiological non-involvement of superior mesenteric vein \\& portal vein.\n* American Society of Anesthesiologists (ASA) scores I \\& II.\n* Patients aged \\> 18 years.\n* Ability to understand and the willingness to sign a written informed consent document\n* Agreement to complete the study\n\nExclusion Criteria:\n\n* Unfit patients for surgery due to severe medical illness.\n* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.\n* Irresectable tumors in diagnostic laparoscopy.\n* History of other malignant disease.\n* Pregnant or breast-feeding women.\n* Patients with serious mental disorders.\n* Patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team according to abdominal imaging data.\n* Pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis\n* Patients refused to participate in the study.","75 Years",{"count":61,"type":21},100,[24],"Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD. In this study, the investigators aim to determine the predictive risk factors for clinically related postoperative pancreatic fistula (CR-POPF) in the preoperative, intraoperative and postoperative period in patients that underwent PD. The total number of 100 participants expected to be included in this research who underwent PD between 2025 and 2026.",[30,65,66,67,68,69,70],"Pancreas Neoplasm","Pancreatic Fistula","Pancreas Adenocarcinoma","Periampullary Cancer","Periampullary Carcinoma","Resectable Pancreatic Cancer","RECRUITING","2026-06-27",{"date":74,"type":42},"2026-07-01",{"date":76,"type":42},"2025-06-20",{"date":78,"type":21},"2026-10-20",{"name":80,"class":49},"Minia University",1,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100436960","pancreatic-cancer-early-detection-consortium-100436960","NCT04970056","Pancreatic Cancer Early Detection Consortium","PRECEDE","Inclusion Criteria:\n\nIndividuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:\n\nCohort 1\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.\n2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+\n5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+\n6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+\n\nCohort 2\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+\n2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family\n3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member\n\nCohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)\n\nCohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.\n\nCohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and\u002For buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.\n\nCohort 6a\n\nIndividuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n\nCohort 6b\n\nIndividuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n3. Diagnosed ≤ age 45\n\nCohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.\n\nCohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.\n\nCyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)\n\nExclusion Criteria:\n\n* Individuals not meeting the criteria above.",true,"90 Years",{"count":92,"type":21},20000,"OBSERVATIONAL","The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and\u002For individuals carrying pathogenic\u002Flikely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.",[30,96,97,98],"Pancreas Cyst","Pancreatic Ductal Adenocarcinoma","Genetic Predisposition","2026-06-23",{"date":101,"type":42},"2026-06-26",{"date":103,"type":42},"2020-09-18",{"date":105,"type":21},"2030-12-31",{"name":107,"class":49},"Arbor Research Collaborative for Health",60,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":4,"leadSponsor":135,"locationsCount":81},"100202701","obtaining-solid-tumor-tissue-from-people-having-biopsy-or-surgery-for-certain-types-of-cancer-100202701","NCT01915225","Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer","Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors","* INCLUSION CRITERIA:\n* Participants must be 2 years of age or older. Note: Participants greater than or equal to 2 and \\\u003C 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the biospecimen sampling (e.g., blood, urine, ascites, bile, or \\[clinically indicated\\] resected tumor tissue) does not add risk to the clinically indicated procedures.\n* Participants who have premalignant, primary, or metastatic solid tumors based upon either radiographic or clinical suspicion, biochemical testing, a genetic predisposition, or histological\u002Fcytological analysis that requires surgery or biopsy as part of the diagnosis, prevention, treatment, and\u002For follow-up.\n* Participants without solid tumors in whom a diagnostic, preventative, or therapeutic intervention is being performed, but for whom surgical quality and safety outcomes data are generated.\n* Participants should have laboratory and physical examination parameters within acceptable limits prior to biopsy or surgery.\n* Participants must be planning to undergo surgery or biopsy as part of their normal treatment plan.\n* Ability of participant, parent\u002Fguardian or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nNone.","2 Years",{"count":118,"type":21},1800,"Background:\n\n\\- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC).\n\nObjectives:\n\n\\- To collect tissue samples for use in studying new ways to treat tumors.\n\nEligibility:\n\n* Adults 18 years and older, with a precancerous or cancerous solid tumor who are scheduled to have surgery or a biopsy at the NIHCC.\n* Children under the age of 18 but who are older than 2 years of age are eligible to be enrolled on the research sample collection portion of this study if they will have a biopsy or surgery as part of their medical care.\n\nDesign:\n\n* Before their procedure, participants will have a small blood sample taken.\n* Some participants will undergo leukapheresis. In this procedure, blood is removed through a tube in one arm and circulated through a machine that removes white blood cells. The blood, minus the white blood cells, is returned through a tube in the other arm. The procedure takes 3-4 hours.\n* For all participants, during the surgery or biopsy, pieces of the tumor and pieces of normal tissue near it will be removed for this study. The rest of the tumor or precancerous growth will be sent to a lab for analysis.\n* Participants will return to the clinic about 6 weeks after the operation for a routine checkup. Some may have to return for additional follow-up.",[121,122,123,124,30],"Colorectal Neoplasms","Gastric Neoplasms","Cholangiocarcinoma","Bile Duct Cancer",[126,127,128,129],"Tissue Procurement","Surgery","Metastasectomy","Natural History","2026-06-17",{"date":132,"type":42},"2026-06-18",{"date":134,"type":42},"2013-07-21",{"name":136,"class":137},"National Cancer Institute (NCI)","NIH",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":50},"100409795","evaluating-the-prognostic-capability-of-ctdna-as-a-biomarker-in-pancreatic-cancer-patients-undergoing-neoadjuvant-chemotherapy-100409795","NCT04616131","Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Biopsy or cytology proven adenocarcinoma of the pancreas\n* No clinical evidence of metastatic disease on imaging\n* Age 18 or older\n* Receiving chemotherapy for non-metastatic pancreatic cancer\n\nExclusion Criteria:\n\n* Biopsy proven metastatic disease",{"count":145,"type":21},500,"For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.",[30],"2026-06-16",{"date":132,"type":42},{"date":151,"type":42},"2020-10-01",{"date":153,"type":21},"2029-10-01",{"name":155,"class":49},"Northwestern University",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":173,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":81},"100641453","transcriptional-pathways-of-surgical-pain-modulated-by-music-therapy-exposure-transpose-100641453","NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study","Inclusion Criteria:\n\n* Age 50 to 80\n* Able to speak and understand English\n* Scheduled to undergo a surgery meeting the following criteria: (1) traditional open surgery (not laparoscopic or robotic) via laparotomy (midline or subcostal incisions), (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces\n* Participant reports pain intensity of 4\u002F10 or above to study staff on day 1 post-surgery or any other day post-surgery through discharge\n\nExclusion Criteria:\n\n* Significant visual impairment that has not been corrected\n* Significant hearing impairment that has not been corrected\n* Significant cognitive impairment that would prevent participant from participating in the study","50 Years","80 Years",{"count":166,"type":21},20,[24],"Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.",[127,170,30,124,171,172],"Stomach Cancer","Liver Cancer","Peritoneal Cancer",[174,175],"Music therapy","Music-assisted relaxation and imagery","2026-06-15",{"date":130,"type":42},{"date":179,"type":21},"2027-01",{"date":181,"type":21},"2027-12",{"name":183,"class":49},"Case Comprehensive Cancer Center",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":81},"100552911","phase-1-study-of-egfrbi-armed-fresh-pbmc-in-metastatic-or-unresectable-pancreatic-cancer-100552911","NCT06479239","Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","Phase I\u002FII Study of Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells (EGFR FPBMC) in Metastatic or Unresectable Pancreatic Cancer","Panc 002","Inclusion Criteria:\n\n1. Histologically confirmed locally advanced pancreatic cancer (LAPC)\u002Funresectable pancreatic cancer (UPC) or metastatic pancreatic cancer (MPC) not eligible for curative intent therapy\n2. Received at least 1 line of chemotherapy and have stable disease (SD) or better for 3 months prior to enrollment. Therapy should consist of either a gemcitabine, 5FU-based (including capecitabine) or albumin-bound paclitaxel-based regimen. Patients with actionable mutations should have received targeted therapy prior to enrollment on trial. Patients who qualify for immunotherapy due to mismatch repair protein\u002Fmicrosatellite stable and tumor mutational burden status should also have received immunotherapy prior to enrollment on trial.\n3. Measurable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n5. Age ≥ 18 years\n6. Females of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment\u002Fregistration\n7. Females of childbearing potential and males must agree to use an effective method for contraception for the duration of the treatment with study drug plus 90 days (duration of sperm turnover). Males must also abstain from sperm donations during study treatment and for at least 90 days after the last dose of study drug.\n8. Adequate organ function within 14 days prior to registration, defined as the following:\n\n   * Absolute neutrophil count \\>= 500\u002Fmm3\n   * Absolute lymphocyte count \\>= 400\u002Fmm3\n   * Platelets \\>= 75,000\u002Fmm3\n   * Hemoglobin \\>= 8 g\u002FdL\n   * Serum creatinine \\\u003C 2.0mg\u002FdL or calculated\u002Fmeasured creatinine clearance \\>= 50 ml\u002Fmin\n   * Bilirubin \\\u003C= 2 mg\u002FdL\n   * Aspartate transferase (AST) and Alanine transaminase (ALT) \\\u003C= 5.0 x upper limit of normal (ULN)\n   * Alpha gal \\\u003C 0.35 IU\u002Fml or \"negative\"\n9. Ability to provide informed consent and provision of written informed consent\n10. Stated willingness to comply with all study procedures and availability for the duration of the study\n11. Adequate cardiac function as defined as:\n\n    * No uncontrolled angina or severe ventricular arrhythmias\n    * No clinically significant pericardial disease\n    * No history of myocardial infarction (MI) in the last year before registration\n    * No Class 3 or higher New York Heart Association Congestive Heart Failure\n\nExclusion Criteria:\n\n1. Known hypersensitivity to cetuximab\n2. Treatment with investigational agent within 3 weeks prior to registration\n3. Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration\n4. Known active liver disease, human immunodeficiency virus (HIV)+ or evidence of active Hepatitis C or B virus; bleeding or condition associated with high-risk bleeding (anticoagulation is allowed)\n5. Active infection; prior antibiotic\u002Fantifungal\u002Fantiviral therapies within 2 weeks prior to registration\n6. History of a myocardial infarction within 1 year prior to registration\n7. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n8. Autoimmune disease that has required systemic treatment with chronic steroids or immunosuppressive therapy in the 2 years prior to registration (thyroxine, insulin, or corticosteroid replacement is allowed)\n9. History or evidence of any condition that might confound the results of the trial, interfere with the subject's participation, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n10. Females must not be currently breast feeding.\n11. The treating investigator feels the patient is not able to be compliant.\n12. History of active Bacillus Tuberculosis (TB).\n13. Has received a live vaccine within 30 days of registration.\n14. Prisoners or patients who are incarcerated.\n15. Patients who are compulsorily detained for treatment of a psychiatric or physical illness.",{"count":193,"type":21},23,[195,196],"PHASE1","PHASE2","The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable pancreas cancer. Participants receive 8 twice weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.",[30,36],"2026-06-12",{"date":148,"type":42},{"date":202,"type":42},"2024-11-06",{"date":204,"type":21},"2031-06",{"name":206,"class":49},"University of Virginia",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":238,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":263},"100520064","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-mesothelin-targeting-logic-gated-car-t-in-participants-with-solid-tumors-that-express-msln-and-have-lost-hla-a02-expression-100520064","NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","A Seamless Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","EVEREST-2","Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of ≥3 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of infusion\n6. Radiotherapy within 28 days of infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion",{"count":216,"type":21},474,[195,196],"The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression.\n\nThe main questions this study aims to answer are:\n\nPhase 1: What is the recommended dose that is safe for patients\n\nPhase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells\n\nParticipants will be required to perform study procedures and assessments, and will also receive the following study treatments:\n\nEnrollment and Apheresis in BASECAMP-1 (NCT04981119)\n\nPreconditioning Lymphodepletion (PCLD) Regimen\n\nTmod CAR T cells at the assigned dose",[220,221,222,223,224,225,30,226,227,228,229,230,231,232,233,234,235,29,236,237],"Solid Tumor, Adult","Colorectal Cancer","NSCLC","Non Small Cell Lung Cancer","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreatic Neoplasm","Colorectal Adenocarcinoma","CRC","Colon Cancer","Rectal Cancer","Cancer","Ovarian Cancer","Ovarian Neoplasms","Mesothelioma","Mesothelioma, Malignant","Lung Cancer","MESOM",[239,240,241,242,243,244,245,246,247,248,249,250,231,251,228,221,236,222,252,237,232,234,253],"CAR T Cell","Solid Tumors","Autologous","T Cell","Mesothelin","MSLN","HLA-A2","Solid Tumors expressing MSLN","Pancreatic","Cell Therapy","Gene Therapy","blocker","PANC","OVCA","Logic-gate","2026-06-10",{"date":199,"type":42},{"date":257,"type":42},"2024-04-03",{"date":259,"type":21},"2029-06",{"name":261,"class":262},"A2 Biotherapeutics Inc.","INDUSTRY",12,{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":50},"100470233","marathon-of-hope-cancer-centres-network-study-for-ontario-mohccn-o-100470233","NCT05403177","Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)","MOHCCN-O","Inclusion Criteria:\n\n1. Patients with histological and\u002For cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy\n2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:\n\n   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)\n   2. Have sufficient biospecimens (tumor and\u002For blood samples) available for more comprehensive molecular and immunophenotypic characterization\n3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.\n4. Participating patients must agree to share their anonymized clinical and genomic data\n\nExclusion Criteria:\n\nNone.",{"count":145,"type":21},"The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients",[27,221,30,274,275,29,276,277,278,236,279,280],"Kidney Cancer","Prostate Cancer","Head and Neck Cancer","Leukemia","Lymphoma","Melanoma","Solid Tumor","2026-06-09",{"date":254,"type":42},{"date":284,"type":42},"2022-06-23",{"date":286,"type":21},"2030-10",{"name":288,"class":49},"University Health Network, Toronto",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":303,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":81},"100528236","phase-1-autologous-car-t-cells-targeting-b7-h3-in-pdac-100528236","NCT06158139","Autologous CAR-T Cells Targeting B7-H3 in PDAC","A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)","Inclusion Criteria:\n\n1. Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for releasing personal health information explained to, understood by, and signed by the subject or legally authorized representative.\n2. Age ≥ 18 years at the time of consent.\n3. Eastern Cooperative Oncology Group of 0-1 Performance Status)\n4. Histological or cytological evidence\u002Fconfirmation of pancreatic ductal adenocarcinoma.\n5. Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after study treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \\\u003C 1% failure rate for protection from pregnancy in the product label.\n6. Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the cell infusion therapy.\n\nExclusion Criteria:\n\n1. Subjects with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n2. Subject is not willing and able to comply with study procedures based on the judgment of the investigator.",{"count":297,"type":21},27,[195],"The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.",[30,301,302],"Relapse","Resistant Cancer",[304],"cellular therapy","2026-06-05",{"date":307,"type":42},"2026-06-08",{"date":309,"type":42},"2024-07-18",{"date":311,"type":21},"2030-04",{"name":313,"class":49},"UNC Lineberger Comprehensive Cancer Center",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":81},"100631001","surgimedia-utilization-of-multimedia-for-enhanced-surgical-consent-100631001","NCT07494994","SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent","SURGIMEDIA","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\n* Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information\n* Subjects is willing and able to comply with study procedures based on the judgement of the investigator.\n* Age ≥ 18 years at the time of informed consent for study participation.\n* Scheduled to undergo a standard of care pancreaticoduodenectomy procedure.\n* English as the patient's self-reported preferred language.\n\nExclusion Criteria:\n\n* Inability to speak English.\n* Dementia altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent as determined by the study physician.\n* Currently pregnant. If a participant becomes pregnant during the study, they will be withdrawn and replaced with a new participant if resources allow.",{"count":108,"type":21},[24],"Informed consent is an ethical and legal component of the pre-procedural process. Informed consent involves the explanation of procedural steps and discussion regarding the risks, benefits, and alternatives of the proposed procedure. The current informed consent process lacks standardization, and patient experience can vary widely depending on the provider obtaining consent. This pilot study aims to ensure high quality informed consent for patients undergoing a complex oncologic operation known as a pancreaticoduodenectomy (Whipple operation), through the creation of an educational video as a method of obtaining informed consent. This study will explore whether the application of an educational video as part of the informed consent process increases patient understanding, comfort, and overall satisfaction throughout the Whipple operative course. The primary objective of this study is to determine whether implementation of a multimedia video as an enhancement to surgical informed consent improves patient satisfaction, promotes understanding, and informs operative expectations. The desired outcome is to standardize the informed consent process to eliminate variability in the quality of the consent process and to mitigate the impact of healthcare barriers such as health literacy and language proficiency in the informed consent process.",[30],[326,327,328,329,330],"informed consent","pancreaticoduodenectomy","Whipple operation","educational video","complex surgical operation","2026-06-04",{"date":307,"type":42},{"date":334,"type":21},"2026-07",{"date":336,"type":21},"2030-01",{"name":313,"class":49},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":348,"conditions":349,"keywords":355,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":369},"100437810","solid-tumor-analysis-for-hla-loss-of-heterozygosity-loh-and-apheresis-for-car-t--cell-manufacturing-100437810","NCT04981119","Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing","BASECAMP-1","Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria\n\n1\\. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n\nPart 1: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n\nPart 2 : Key Inclusion Criteria\n\n1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n2. Participants are germline HLA-A\\*02 heterozygous confirmed by HLA typing.\n3. Primary tumor tissue showing LOH of HLA-A\\*02 by NGS testing.\n4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.\n\nPart 2: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n4. Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter.\n5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course).\n6. Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement.\n7. In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.",{"count":347,"type":21},200,"Objective:\n\nTo collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment.\n\nDesign:\n\nThis is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.",[220,221,223,36,228,222,30,234,232,233,350,235,351,231,352,353,354],"Ovarian Carcinoma","Mesothelioma; Lung","Triple Negative Breast Cancer (TNBC)","Renal Cell Carcinoma (Kidney Cancer)","Head and Neck Squamous Cell Carcinoma HNSCC",[356,357,358,359,360],"CAR T Cell Therapy","Next Generation Sequencing","Leukapheresis","Apheresis","Immunotherapy","2026-05-29",{"date":363,"type":42},"2026-06-02",{"date":365,"type":42},"2021-10-29",{"date":367,"type":21},"2029-04",{"name":261,"class":262},16,{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":392},"100638938","a-study-of-magnetic-resonance-imaging-of-the-pancreas-for-cancer-screening-100638938","NCT07612046","A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening","Pilot Study of a Dedicated MR of the Pancreas: Improving Screening for Patients at High Risk for Pancreas Cancer","Inclusion Criteria:\n\n* Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual\n* Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first\u002Fsecond-degree relative with pancreas cancer\n* Pathogenic mutation in CDKN2A\u002Fp16, STK11, PRSS1, SPINK1\u002FPST1, CTRC, CPA1, ATM, or BRCA2\n* Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+\n\nFor this pilot MRP study, we will additionally apply the following Criteria:\n\n* Consents to follow-up contact\n* US residents\n* Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)\n* No metallic artifacts covering the pancreas on prior MRCP\n* Scheduled for endoscopic ultrasound\n* No new contraindications for MRI (e.g. new MR unsafe device)\n* No history of claustrophobia or use of anxiolytic on prior MRI\n* No history of abdominal surgery that may affect interpretation of either EUS or MR\n* No medical conditions that confers increased and\u002For unacceptable risk for anesthesia\n\nWe will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \\~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.\n\n* Documentation of Disease\n\n  o No pathologic confirmation of disease is necessary\n* Definition of Disease N\u002FA\n* Not Pregnant and Not Nursing\n* Required Organ Function N\u002FA\n\nExclusion Criteria:\n\n\\-",{"count":378,"type":21},79,"The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.",[36,30],[36,30,382,383],"Memorial Sloan Kettering Cancer Center","26-174","2026-05-21",{"date":386,"type":42},"2026-05-28",{"date":388,"type":42},"2026-05-20",{"date":390,"type":21},"2028-05-20",{"name":382,"class":49},7,{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":81},"100639337","scheduled-meditation-for-improving-postoperative-outcomes-in-patients-undergoing-pancreatectomy-100639337","NCT07608458","Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy","Scheduled Meditation for Perioperative Optimization: A Randomized Controlled Trial on Postoperative Outcomes, Pain, Anxiety, Insomnia, Stress, and Mobility in Pancreatectomy Patients","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Willing to install required apps on personal smartphone\n* Willing to wear a Garmin wearable device throughout the study\n* Age: ≥ 18 years\n* Ability to read and understand English for questionnaires\n* Owns a smartphone\n* Comfortable with routine smartphone use\n* Scheduled to undergo pancreatectomy\n\nExclusion Criteria:\n\n* Participants with prior formal training in meditation or mindfulness (e.g., completion of structured courses, workshops, or certification programs)\n* Participants who currently engage in a structured meditation or mindfulness practice, including regular use of mobile applications (e.g., Headspace, Calm, or similar platforms) or other formalized routines",{"count":401,"type":21},70,[24],"This clinical trial tests the feasibility and how well a scheduled meditation intervention works to improve postoperative outcomes such as pain, anxiety, insomnia, stress and mobility for patients undergoing pancreatectomy. Many patients undergoing pancreatectomy surgery report clinically important fatigue, pain, and\u002For reduction in quality of life. Meditation is a behavioral intervention that has been studied in a variety of medical and surgical settings, where it has been associated with reductions in pain, anxiety, blood pressure, and lack of sleep, and in some cases with decreased pain and shorter length of stay. The meditation intervention using Headspace is an easily accessible and interactive way to complete scheduled meditation. This may improve postoperative outcomes for patients undergoing pancreatectomy.",[405,30,406],"Hepatocellular Carcinoma","Biliary Tract Neoplasms","2026-05-19",{"date":409,"type":42},"2026-05-27",{"date":411,"type":21},"2026-06-25",{"date":413,"type":21},"2026-11-25",{"name":415,"class":49},"City of Hope Medical Center",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":431,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":81},"100536304","equity-gi-a-prospective-study-to-enhance-quality-inclusivity-and-trial-participation-in-black-patients-with-gastrointestinal-cancer-100536304","NCT06263088","EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.","Inclusion Criteria:\n\n1. Adult ≥ 18 years old.\n2. Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor.\n3. Patient able and willing to comply with study procedures\n4. The patient is able to understand and willing to sign and date the written informed consent form at the screening visit.\n\nExclusion Criteria:\n\n* NONE",{"count":347,"type":21},[24],"This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin).\n\nThis study has 3 components as follows-\n\n1. Ensuring appropriate biomarker testing and evidence-based care: Biomarkers are molecules in the tumor or blood that indicate normal or abnormal processes in participant's body and may indicate an underlying condition or disease. Various molecules, such as DNA (genes), proteins, or hormones, can serve as biomarkers since they all indicate something about participant's health. Biomarker testing can also help choose participant's treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to participant's treating physician. Participants will receive standard-of-care treatment if participant enroll in this study. Participant will not receive any experimental treatment.\n2. Assistance with clinical trial enrollment. The study team will help participants enroll in a clinical trial appropriate for participant's condition. However, enrolling in a clinical trial is totally up to the participant.\n3. Health literacy: The study team will provide information relevant to participant's diagnosis to enrich participant's understanding of participant's condition and treatment. Investigator will provide questionnaires to assess participant's understanding before and after participant's have been provided with educational\u002Finformational material appropriate for participant's diagnosis.",[426,229,230,427,428,170,429,30,171,430],"Gastrointestinal Cancer","Anal Cancer","Esophageal Cancer","Appendix Cancer","Neuroendocrine Tumors",[432,433],"Gastrointestinal cancer","African Americans",{"date":435,"type":42},"2026-05-22",{"date":437,"type":42},"2024-12-01",{"date":439,"type":21},"2026-09-30",{"name":183,"class":49},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":50},"100561689","phase-3-extending-outcomes-for-pancreas-cancer-patients-with-nominal-oligometastatic-disease-expand-a-randomized-phase-iii-trial-100561689","NCT06593431","Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial","Inclusion Criteria:\n\nAge 18\n\nHistologically or cytologically confirmed pancreatic ductal adenocarcinoma.\n\nHistologic \u002F cytologic confirmation of pancreatic ductal adenocarcinoma may come from the primary tumor (i.e., via FNA at initial diagnosis). Histological\u002Fpathologic confirmation of distant metastatic disease is not required if clinical and radiographic consensus is that the patient has distant metastatic disease.\n\nEastern Cooperative Oncology Group (ECOG) performance status ≤2\n\nCandidate for MDT (including radiation therapy, surgical resection, ablation, and embolization) to all sites of disease including oligometastatic sites and if present intact primary \u002F regional nodal disease.\n\nBetween one and five distant metastatic lesions, counted as follows: each lesion (not site) will be counted as one, with the exception of metastatic lymph node stations, which will collectively count as one lesion. Regional nodal stations will be counted as a collective single lesion if present. All progressive lesions must be amenable to local therapy as noted in criterion 4.2.1.4 above.\n\nCounting of oligometastatic nodal disease will be based on nodal chains. A nodal chain will be considered a single metastatic lesion if the presence of that node results in the patient as having M1 disease per the TNM staging system, AJCC version 8.0. In addition, one of the following criteria must be met: a) ≥1 LN meets radiologic criteria for metastatic disease via RECIST 1.1 (short axis ≥15mm), b) pathologic assessment has confirmed the presence of metastatic cancer cells, and\u002For c) the LN exhibits imaging signal characteristic of a metastatic lesion (e.g. FDG avidity, contrast enhancement, etc.). In the event of ambiguity or equivocal findings, the principal investigator or co-principal investigator will make a final determination of whether criteria are met. The following caveats apply:\n\nIn patients with a LN exhibiting a short axis ≥15mm and who have other diagnoses that can produce enlarged LNs (e.g. indolent CLL, sarcoidosis, etc…) or a prior history of benign enlarged LNs will not be considered to have metastatic disease per the discretion of the treating physician.\n\nLN chains that occur bilaterally will be considered separate metastatic sites. For example, left axilla LNs will counted separately from right axilla LNs.\n\nThe following midline LN chains will be counted as 1 metastatic site: mediastinal, para-aortic, mesenteric.\n\nThe following bilateral LN chains will be counted as 1 metastatic site for unilateral involvement, and 2 for bilateral for involvement: preauricular, cervical and occipital, supraclavicular, infraclavicular, pectoral, axillary, hilar, epitrochlear and brachial, iliac, inguinal and femoral, popliteal.\n\nBaseline imaging must include a scan done within 4 weeks prior to randomization, demonstrating oligometastatic disease by RECIST (v1.1) criteria compared to pre-baseline imaging.\n\nBaseline imaging must be done within 4 weeks prior to randomization, and the following imaging is required: PET\u002FCT scan or CT scan of the chest\u002Fabdomen\u002Fpelvis. MRI may be substituted as indicated (i.e., CT scan of chest plus MRI abdomen\u002Fpelvis).\n\nDiagnostic laparoscopy may be indicated prior to enrollment if any concern for peritoneal disease \u002F carcinomatosis is present, at the investigator's discretion. Presence of peritoneal carcinomatosis will exclude the patient from this trial as below. Indications for peritoneal carcinomatosis may include findings concerning for but not definitive for peritoneal disease on diagnostic imaging, elevated CA-19-9, and clinical symptoms concerning for peritoneal disease.\n\nPatients referred for the study that require immediate MDT can receive treatment to CNS lesions or other symptomatic lesions prior to randomization, but these lesions will be counted towards the total number of oligometastatic lesions.\n\nPatients with \\>5 discrete metastatic sites previously with subsequent 'induction' of oligometastatic disease (\\<=5 discrete sites; induction via response to systemic therapy) may be eligible if 5 or fewer metastatic disease sites have been present \u002F noted radiographically for a minimum of 6 months, and pending principal investigator review\u002Fdiscretion.\n\nFemales of childbearing potential must not be breast feeding and must have a negative serum or urine pregnancy test and must agree to use adequate contraception from the time of screening until 3 months after discontinuation of the study medication. Acceptable methods of contraception include total and true sexual abstinence, tubal ligation, hormonal contraceptives that are not prone to drug-drug interactions (IUS Levonorgestrel Intra Uterine System (Mirena), Medroxyprogesterone injections (Depo-Provera), copper-banded intra-uterine devices, and vasectomized partner. All hormonal methods of contraception should be used in combination with the use of a condom by their sexual male partner. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Women will be considered post-menopausal if they have been amenorrheic for the past 12 months without an alternative medical cause. The following age-specific requirements must also apply: Women \\< 50 years old: they would be considered post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of exogenous hormonal treatments. The levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) must also be in the post-menopausal range (as per the institution). Women ≥ 50 years old: they would be consider post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of all exogenous hormonal treatments, or have had radiation-induced oophorectomy with the last menses \\> 1 year ago, or have had chemotherapy-induced menopause with \\>1 year interval since last menses, or have had surgical sterilization by either bilateral oophorectomy or hysterectomy.\n\nNon-sterilized males who are sexually active with a female partner of childbearing potential must use adequate contraception for the duration of the study and 6 months after the last dose of study medication. Adequate contraception methods include: birth control pills (e.g. combined oral contraceptive pill), barrier protection (e.g. condom plus spermicide, cervical\u002Fvault cap or intrauterine device), and abstinence. Patients should not father a child for 6 months after completion of the study medication. Patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing the study medication. If male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of the study medication.\n\nDemonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment:\n\nExclusion Criteria\n\nMetastatic effusion (e.g. pleural effusion or ascites). Note that patients with an effusion that is too small to sample will be eligible for the trial.\n\nLeptomeningeal disease.\n\nPeritoneal carcinomatosis.\n\nCognitively impaired subjects (e.g. inability to sign informed consent.)\n\nAny condition that, in the opinion of the investigator, would interfere with the study treatment or interpretation of the study results.\n\nDiffuse bone marrow involvement as defined by disease involvement of a BM biopsy from a site that does not have radiologic evidence of a bone metastasis.\n\nMore than 4 prior lines of systemic therapy to treat metastatic disease.\n\nDiagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe delivery of radiotherapy. Such patients may be eligible if dispositioned to non-radiotherapy MDT.\n\nKnown psychiatric or substance abuse disorder\u002Fs that would interfere with trial participation.\n\nConcurrent (synchronous or metachronous) other primary malignancy that in the opinion of the treating physician team presents a substantial risk to the patient's life as a competing risk of death (against the primary oligometastatic pancreatic cancer being considered for MDT as part of this trial).",{"count":448,"type":21},80,[450],"PHASE3","The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).",[30,453],"Oligometastatic","2026-05-18",{"date":388,"type":42},{"date":457,"type":42},"2024-10-23",{"date":459,"type":21},"2029-06-29",{"name":461,"class":49},"M.D. Anderson Cancer Center",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":471,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":479,"leadSponsor":481,"locationsCount":4},"100638325","statewide-unified-network-for-remote-intervention-of-strength-and-exercise-100638325","NCT07596732","Statewide Unified Network for Remote Intervention of Strength and Exercise","SUNRISE","Inclusion Criteria:\n\n* Gastrointestinal cancer (esophageal, gastric, pancreatic, colon, and rectal) treated with chemotherapy (and other treatments, as clinically indicated) before surgery OR Lung cancer (non-small cell and small-cell) treated with chemotherapy (and other treatments, as clinically indicated) for advanced- or extensive-stage disease.\n* Completion of the modified version of the Physical Activity Readiness Questionnaire.\n\nExclusion Criteria:\n\n* Actively treated for another non-gastrointestinal or non-lung malignancy (surveillance with observation is allowed).\n* Engage in more than 150 minutes per week of aerobic physical activity and two or more sessions of muscle strengthening activity per week over the last three months (self-report).\n* Unable to walk for 6 minutes or two city blocks independently (self-report).\n* Enrollment in another study that intervenes upon physical activity, diet, or body composition as a primary objective (self-report).\n* Unable to read and speak English.\n* No access to a reliable internet connection.\n* Currently an AdventHealth employee.",{"count":470,"type":21},120,[24],"This study will evaluate whether a remotely delivered exercise program can improve chemotherapy tolerability in patients with gastrointestinal or lung cancer receiving chemotherapy.\n\nIn this decentralized, digital randomized clinical trial, up to 120 adults with gastrointestinal or lung cancer will be randomized to either a home-based aerobic and resistance exercise program or home-based progressive stretching program. All study activities will be conducted remotely using digital technologies and home-based assessments. Participants in both groups will receive Bluetooth-enabled wearable devices for monitoring physical activity, body weight, blood pressure, and other health measures.\n\nThe primary objective is to determine whether exercise improves chemotherapy relative dose intensity compared with stretching. The intervention will continue throughout chemotherapy treatment or for up to 32 weeks.",[474,475,30,229,230,236],"Gastric Cancer (Diagnosis)","Esophagus Cancer","2026-05-13",{"date":407,"type":42},{"date":74,"type":21},{"date":480,"type":21},"2027-12-31",{"name":482,"class":49},"AdventHealth Translational Research Institute",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":496,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":508},"100535493","promoting-ct-engagement-for-pancreatic-cancer-with-app-100535493","NCT06252545","Promoting CT Engagement for Pancreatic Cancer With App","PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study","PROCLAIM","Inclusion Criteria\n\nParticipants must meet the following inclusion criteria in order to participate in communication \\& education interview component of the study:\n\n1. Informed consent obtained to participate in the study\n2. 18 years or older\n3. English speaking\n4. Able and willing to participate in a 1-hour interview\n5. History of pancreatic cancer diagnosis\n6. Identify as Black\n\nExclusion Criteria:\n\nAll participants meeting any of the following exclusion criteria will be excluded from the study:\n\n1. Inability to read and speak English\n2. Dementia altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent as determined by the study physician.",{"count":492,"type":21},26,[24],"To develop a culturally tailored informational mobile application and test whether it will increase participation among Black pancreatic cancer subjects in clinical trial discussions with their care team.\n\nThis project aims to identify and address barriers to enrollment of Black subjects in pancreatic cancer clinical trials using a culturally informed mobile health application to promote participation.\n\nThe clinical trial education and communication needs of Black people with pancreatic cancer will be determined. A new mHealth application for clinical trial education and communication tailored to subject needs will be developed. It was hypothesized that a culturally tailored informational mobile application will increase the participation of Black subjects in clinical trial discussions with their care team among the target population.\n\nThis study focuses on Black pancreatic cancer subjects, who experience higher mortality rates and lower clinical trial participation than White subjects. Research shows that the disparity between clinical trial participation is in part due to inequitable recruitment practices. This study will use mobile application technology (mHealth app) as an educational, communication, audit, and feedback tool to promote patient-initiated clinical trial discussions among Black people with pancreatic cancer and their cancer care team.",[30],[497,498,499],"ethnicity","black","application","2026-05-11",{"date":502,"type":42},"2026-05-14",{"date":504,"type":42},"2024-02-02",{"date":506,"type":21},"2027-02-01",{"name":313,"class":49},2,{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":22,"phases":519,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":81},"100558333","phase-1-mt-601-administered-to-patients-with-locally-advanced-unresectable-or-metastatic-pancreatic-cancer-100558333","NCT06549751","MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","A Phase 1 Study With Expansion of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PANACEA)","PANACEA","Inclusion Criteria:\n\n1. Informed Consent\n2. Age ≥ 18 years\n3. ECOG performance status of 0 to 1\n4. Cytologically or histologically confirmed, locally advanced, unresectable or metastatic pancreatic adenocarcinoma (pancreatic carcinomas with at least some component of adenocarcinoma included).\n5. Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n6. Prior receipt of at least 4 doses (\\~2 months) of FFX or NLX with plans for completion of 12 doses (\\~6 months)\n7. Absence of progression during treatment with FFX or NLX (eg. CR, PR, or SD at study entry)\n8. Adequate pulmonary function with partial pressure of oxygen (pO2) on room air of at least 90%\n9. Adequate cardiac function with an ejection fraction ≥ 45%\n10. Adequate organ function, as defined below:\n\n    * Absolute neutrophil count (ANC) ≥1.0 × 109\u002FL (growth factor support allowed)\n    * Platelets ≥75,000\u002Fmm3 (supportive medications allowed)\n    * Hemoglobin ≥9 gm\u002FdL (transfusion allowed)\n    * Total bilirubin ≤2.0 × ULN unless considered due to Gilbert's syndrome in which case, ≤ 3.0 x ULN\n    * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN OR ≤5 × ULN if known tumor involvement of liver\n    * Serum creatinine ≤2 × ULN OR estimated glomerular filtration rate (using institutional standard) ≥50 mL\u002Fmin\n11. Willingness to use adequate contraception throughout study and for a period of 3 months after last dose of any study drugs\n\nExclusion Criteria:\n\n1. Known CNS metastases or meningeal carcinomatosis unless treated and controlled for ≥ 3 months prior to the first administration of MT-601 without the need for increasing doses of steroids\n2. Other known active cancer likely to require additional treatment in the next 2 years unless approved by Medical Monitor\n3. Active bacterial, viral, or fungal infection requiring systemic therapy. Patients may be re-evaluated for eligibility upon completion of infection treatment.\n4. Significant cardiovascular risk (eg, coronary stenting within 4 weeks, myocardial infarction within 6 months)\n5. Diagnosis of significant immunodeficiency that in the Investigator or Medical Monitor's judgment would preclude participation in the study.\n6. Administration of systemic steroid therapy (\\> 10 mg\u002Fday of prednisone equivalent) ≤ 7 days prior to the first administration of MT-601\n7. Active autoimmune disease that required systemic treatment in the past 2 years (replacement therapies excluded \\[eg, thyroxine, insulin, physiologic corticosteroids\\])\n8. History of solid organ or hematologic transplant\n9. Known HIV\n10. Evidence of active hepatitis B as defined by:\n\n    1. Positive hepatitis B surface antigen (HBsAg), or\n    2. Negative HBsAg but a positive hepatitis B surface antibody (HBsAb) or positive hepatitis B core antibody (HBcAb) with a positive hepatitis B virus (HBV) DNA\n11. Evidence of active hepatitis C as defined by:\n\n    a. Positive anti-hepatitis C virus antibody (HCVAb) with a positive hepatitis C virus (HCV) RNA by PCR\n12. Pregnant or currently breast-feeding\n13. Psychiatric illness\u002Fsocial situations that would interfere with compliance with study requirements",{"count":518,"type":21},38,[195],"The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\\[s\\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.",[30,522,523],"Pancreatic Cancer Metastatic","Pancreatic Cancer (Unresectable)","2026-05-10",{"date":476,"type":42},{"date":527,"type":21},"2026-07-16",{"date":529,"type":21},"2028-09-16",{"name":531,"class":262},"Marker Therapeutics, Inc.",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":542,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":50},"100626490","impact-of-consumption-of-ultra-processed-foods-in-individuals-at-high-risk-of-cancer-100626490","NCT07436312","Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer","Impact of a Mixed Intervention Aiming to Decrease the Consumption of Ultra-processed Foods on the Global Diet Quality in Individuals at High Risk of Cancer","U-TRANS","Inclusion Criteria:\n\n1. Age \\> 18 years,\n2. Individuals at increased risk of different cancers as defined within the Interception program,\n3. With a baseline WCRF score ≤ 5 at entry in the Interception program,\n4. Agreeing to participate and who have given their written agreement for the study,\n5. Agreeing to fill in the questionnaires on the dedicated platform for the duration of the study,\n6. Participant have and accept to use their smartphone,\n7. All participants must understand spoken and written French language\n\nExclusion Criteria:\n\n1. Psychiatric disorders or cognitive impairments precluding participation,\n2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.",{"count":541,"type":21},170,[24],"The U-TRANS study was initiated by Gustave Roussy, which is its sponsor\\*. It is part of the Interception Program and aims to reduce the consumption of ultra-processed foods in order to improve the overall quality of the diet among people at high risk of cancer (WCRF score ≤ 5, corresponding to low adherence to nutritional cancer prevention recommendations: eating a diet rich in whole grains, vegetables, fruit and fibre, and limiting ultra-processed foods, red meat, processed meats, sugary drinks and alcohol). It assesses the impact of a digital intervention (based on the use of the Open Food Facts app) as a complement to the nutritional education provided by the Interception program.",[27,30,229,545,546,547],"Lynch Syndrome","Germline BRCA1 Gene Mutation","Germline BRCA2 Gene Mutation","2026-05-05",{"date":550,"type":42},"2026-05-08",{"date":552,"type":42},"2026-05-04",{"date":554,"type":21},"2028-03",{"name":556,"class":49},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":22,"phases":567,"briefSummary":568,"conditions":569,"keywords":570,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":508},"100620230","phase-2-axelopran-for-advanced-cancer-in-patients-receiving-opioids-100620230","NCT07354919","Axelopran for Advanced Cancer in Patients Receiving Opioids","A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)","AxeCan","Inclusion Criteria:\n\n1. Adults (aged 18 or more at enrollment).\n2. Histologically or cytologically proven cancer of the prostate (carcinoma), breast (carcinoma), pancreas (carcinoma), and lung (non-small cell lung carcinoma (NSCLC)) that has relapsed or progressed on or after a standard systemic treatment that has included cytotoxic chemotherapy.\n3. Advanced stage (locally advanced or metastatic) with no definitive plans for curative-intent therapy.\n4. A minimum life expectancy of at least 2 months at the time of the screening visit.\n5. Current use of an opioid medication with an average of 5mg OME\u002Fday over the past 3 days.\n6. At least one measurable lesion meeting RECIST v1.1 criteria.\n7. At least 2 weeks since last cancer-directed therapy:\n\n   1. NSCLC and pancreatic cancer must have received at least one line of systemic cytotoxic chemotherapy (+\u002F- immune checkpoint inhibitor) in the locally advanced\u002Fmetastatic setting.\n   2. Breast cancer must be considered refractory to hormone therapy (i.e., progressed on standard estrogen blocking therapy) or hormone negative (i.e., estrogen and progesterone-receptor negative) and have received at least one line of systemic cytotoxic chemotherapy in the locally advanced\u002Fmetastatic setting.\n   3. Prostate cancer must be considered metastatic castrate-resistant prostate cancer (mCRPC) and have progressed on at least one androgen receptor pathway inhibitor (ARPI) and docetaxel. Docetaxel could be given in the metastatic castrate-sensitive setting, and\u002For later in the mCRPC setting. Baseline testosterone level must be \\\u003C50 ng\u002FdL and surgical or ongoing medical castration must be maintained throughout the duration of the study.\n8. Patients must a) have relapsed or progressed on or after all standard therapy, b) be intolerant to standard therapy, c) not have standard therapy available that confers a significant clinical benefit, d) decline other standard therapy or agree with treating oncologist that a period of active surveillance off therapy is reasonable.\n9. Clinician and patient are willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to next line of therapy at any time if a patient's clinical course changes and urgent new treatment is required. Patients will be allowed to remain on axelopran if that occurs.\n\n   a) Planned palliative radiation therapy should be completed prior to study enrollment. Palliative radiation done during the primary study period would be considered next line of cancer therapy.\n10. Must be willing to report baseline and required patient-reported outcomes and report daily bowel movement frequency for monitoring stool changes.\n11. For a female subject of childbearing potential, must have documentation of a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1. All women are considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 2 years) or documented to be surgically sterile (bilateral tubal ligation or hysterectomy).\n12. Sexually active subjects must use a highly effective method of contraception during the study and for at least 90 days after completion of study drug dosing.\n\n    1. A highly effective method of birth control is defined as one that results in a low failure rate (i.e., \\\u003C 1% per year) when used consistently and correctly, such as condom + diaphragm, condom + spermicide, diaphragm + spermicide, or intrauterine device (IUD) with documented failure rate of \\\u003C 1% per year, or oral\u002Finjectable\u002Fimplanted hormonal contraceptives used in combination with an additional barrier method.\n    2. Males should refrain from donating sperm during the study and for 90 days after completion of study drug.\n\nExclusion Criteria:\n\n1. Any previous gastrointestinal surgery, except uncomplicated appendectomy or cholecystectomy.\n2. Any of the included cancer cohorts where active malignancy causes direct extension\u002Finvasion of the GI tract from local spread or distant metastasis.\n3. Current, active, untreated brain metastases.\n4. History of fecal incontinence\u002Fimpaction; irritable bowel syndrome; inflammatory bowel disease; intestinal obstruction; GI or pelvic disorders known to affect bowel transit, produce GI obstruction, or contribute to bowel dysfunction; fecal impaction requiring medical intervention within 1 month of enrollment.\n5. Subject is unable to eat, drink, take, or hold down oral medications.\n6. Use of buprenorphine, alvimopan, naltrexone, methylnaltrexone, naloxone, lubiprostone, linaclotide, or tapentadol therapy within 14 days before enrollment and inability or unwillingness to discontinue use until the end of the study.\n7. Receipt of strong inhibitors of CYP3A4 (e.g., antifungal azoles, grapefruit juice) or strong inducers of CYP3A4 (e.g., rifampin or carbamazepine), including any herbal medications such as St. John's Wort, within the last 14 days or 5 half-lives, whichever is longer, prior to study drug administration.\n8. Receipt of inhibitors of p-glycoprotein (P-gp) within the last 14 days prior to study drug administration.\n9. Receipt of anti-VEGF therapies (i.e. bevacizumab) within the last 30 days prior to study drug administration.\n10. Subjects with clinically significant abnormal ECG at screening or before randomization in the opinion of the Investigator, or a QTc \\> 470 msec (per Fridericia's correction).\n11. Presence of unstable diseases, in the opinion of the Investigator, such as cardiovascular (e.g., acute myocardial infarction or acute coronary syndrome \\\u003C 3 month history), respiratory (e.g., requires oxygen), gastrointestinal (e.g., symptomatic diverticulitis, irritable bowel syndrome \\[IBS\\], etc.), endocrine (e.g., uncontrolled diabetes or A1c \\> 10%), hematologic, neurologic, psychiatric (e.g., schizophrenia, unstable anxiety disorder, acute psychosis, depression with suicidal ideation, etc.), or any other significant conditions that may affect subject assessment.\n12. Any other condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety, efficacy, or tolerability of the investigational drug, or prevent compliance with the study protocol.\n13. Women who are pregnant, breastfeeding, or of childbearing potential without the use of birth control.",{"count":566,"type":21},34,[196],"The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main questions it aims to answer are:\n\n* Does axelopran show a signal for efficacy in slowing tumor progression?\n* Is axelopran safe and tolerable for long-term use in this patient population?\n* Does axelopran show a signal for efficacy in improving bowel function and quality of life?\n* Does axelopran show a signal for efficacy in reducing systemic inflammation, cachexia, and prognostic serum biomarkers of inflammation?\n\nPatients will take axelopran as monotherapy after relapse or progression on or after standard systemic therapy. Clinician and patient must be willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to the next line of therapy whenever deemed clinically necessary.\n\nParticipants will:\n\n* take oral axelopran capsules daily for up to 1 year, or longer if deriving benefit\n* attend 10 in-person study visits, each lasting approximately 1-2 hours\n* complete study procedures including but not limited to imaging exams, blood draws, electronic health surveys, and physical assessments",[27,236,30,275],[571,572,573],"cancer","axelopran","opioids","2026-04-29",{"date":548,"type":42},{"date":577,"type":42},"2026-04-27",{"date":579,"type":21},"2028-11-01",{"name":581,"class":49},"HealthPartners Institute",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":81},"100533652","molecular-profile-related-individualized-targeted-therapy-in-resected-pancreatic-cancer-with-high-risk-of-cancer-recurrence-100533652","NCT06228599","Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence","PROTECT-PANC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology).\n3. Pancreatic tumor is surgically removed and\n\n   1. patient has received multimodal therapy (neoadjuvant, sandwich or adjuvant chemotherapy ± radiation) or\n   2. patient is ineligible for or refuses multimodal therapy.\n4. Patient has one of the following:\n\n   1. Post-surgical cancer antigen (CA) 19-9 elevation (\\> 35 U\u002FmL at least 6 weeks post-surgical resection) in the setting of bilirubin \\\u003C 2 mg\u002FdL (unless bilirubin elevation is consistent with Gilbert's syndrome) OR\n   2. High-risk pathological features, defined as positive surgical margin or lymph node involvement in cancer.\n5. Patient has no definitive measurable disease recurrence or metastatic disease at the time of first post-surgical imaging (in those with high-risk pathological features) or within four weeks of elevated CA 19-9 value as evidenced by appropriate imaging.\n6. Laboratory values:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.0 × 109\u002FL.\n   2. Platelet count ≥ 75,000\u002Fmm\\^3 (125 × 109\u002FL).\n   3. Hemoglobin (Hgb) ≥ 8 g\u002FdL.\n   4. aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT) serum glutamate-pyruvate transaminase (SGPT) ≤ 5 × upper limit of normal range (ULN).\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status \\\u003C 3.\n8. At the time of treatment, patient should be off other anti-tumor agents for at least five half-lives of the agent or three weeks from the last day of treatment, whichever is shorter.\n9. Able to swallow and retain oral medication, if needed.\n10. Pregnancy It is not known what effects matched therapy has on human pregnancy or development of the embryo or fetus. Therefore, female subjects participating in this study should avoid becoming pregnant, and male subjects should avoid impregnating a female partner. Nonsterilized female subjects of reproductive age and male subjects should use effective methods of contraception through defined periods during and after study treatment as specified below.\n\n    Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n    * Not a female of childbearing potential (FCBP), defined as all female patients that were not in post-menopause for at least one year or are surgically sterile, OR\n    * An FCBP must have a negative serum pregnancy test and agree to use at least one form of pregnancy prevention during the study for at least one month after treatment discontinuation unless otherwise noted by the agent(s) USPI, which the FCBP must follow.\n\n    Male participants: A male participant, even if surgically sterilized (i.e., status post vasectomy), must use a form of barrier pregnancy prevention approved by the investigator or treating physician during the study and for at least one month after treatment discontinuation and refrain from donating sperm during this period unless otherwise noted by the agent(s) USPI, which the male participant must follow.\n11. Patient must be presented at the Molecular Tumor Board (MTB) and agree to receive the MTB-recommended therapy.\n12. Ability to understand a written informed consent document, and the willingness to sign it.\n\n    1. Patients presented at the MTB prior to signing consent are eligible to be on study. Patients do not need to be presented again at the MTB prior to starting therapy on trial unless six months elapse between consent and start of study treatment.\n\nExclusion Criteria:\n\nA potential study subject who meets any of the following exclusion criteria is ineligible to participate in the study.\n\n1. CA 19-9 non-producers, unless high-risk pathological features present.\n2. Receiving concomitant investigational agent(s) for pancreatic ductal adenocarcinoma (PDAC).\n3. Radiographic evidence of metastatic disease.\n4. Inability to ingest study drugs by mouth.\n5. Diarrheal bowel movements \\> 6 per day postoperatively on maximal medical therapy.\n6. Patient has active, untreated, or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic intravenous therapy.\n7. Patient has undergone or planned major surgery other than diagnostic surgery (i.e., surgery done to obtain a biopsy for diagnosis without removal of an organ) within four weeks prior to Day 1 of study therapy.\n8. Patient has a history of allergy or hypersensitivity to the study drug(s) or any of the excipients.\n9. Uncontrolled concurrent illness, including, but not limited to, unstable angina pectoris, uncontrolled and clinically significant cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n10. Is pregnant or breastfeeding or any patient with childbearing potential not using adequate pregnancy prevention.",{"count":590,"type":21},40,[24],"This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.",[30],[595,596,597],"pancreatic cancer","molecular profile","targeted therapy",{"date":548,"type":42},{"date":600,"type":42},"2024-02-29",{"date":602,"type":21},"2029-01-31",{"name":604,"class":49},"Medical College of Wisconsin",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":613,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":81},"100519958","phase-2-sintilimab-combined-with-chemotherapy-and-radiotherapy-in-patients-with-inoperable-pancreatic-cancer-100519958","NCT06050317","Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial","Inclusion Criteria:\n\n* ECOG PS 0-1\n* Pathological tissue-confirmed unresectable locally advanced pancreatic cancer\n* Pancreatic cancer patients who have not received systemic anti-tumor therapy\n* Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards\n* A life expectancy of \\> 3 months\n* Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells\u002FL, platelets ≥ 75×109 cells\u002FL, hemoglobin ≥ 9.0 g\u002Fdl\n* AST\\\u003C2.5 × ULN(Upper Limit of Normal), ALT\\\u003C2.5 × ULN,creatinine ≤1.5xULN, total bilirubin \\\u003C ≤1.5 X ULN.\n\nExclusion Criteria:\n\n* Diagnosed with other malignant diseases other than pancreatic cancer within three years before enrollment\n* Patients who are currently participating in interventional clinical research treatment or have received other research drugs or used research devices within four weeks before enrollment\n* Patients who have previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors\n* Patients who have received systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment\n* Abnormal results of blood routine examinations and liver and kidney and coagulation tests\n* Abnormal function of major organs (14 days before enrollment)\n* Women who are pregnant\n* Inability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.",{"count":7,"type":21},[196],"Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.",[30],[617,618,619,620],"Immunothrapy","Chemotherapy","Radiothrapy","Pancreatic cancer",{"date":622,"type":42},"2026-05-01",{"date":624,"type":42},"2023-08-18",{"date":626,"type":21},"2026-08-18",{"name":628,"class":49},"Shandong Cancer Hospital and Institute",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":22,"phases":637,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":369},"100558331","clinical-performance-of-medical-device-software-lipidica-10-for-processing-data-generated-by-lipidomic-analysis-in-pancreatic-cancer-screening-100558331","NCT06549725","Clinical Performance of Medical Device Software \"Lipidica 1.0\" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening","Inclusion Criteria Arm1:\n\n* Age ≥ 18 years\n* Signed informed consent\n* Histologically confirmed diagnosis of resectable PaC\n\nExclusion Criteria Arm 1:\n\n* History of any other cancer disease\n* Present incurable malignancy\n* Unfit for radical curative resection of the tumor\n* Vegan or vegetarian diet\n\nInclusion Criteria Arm2:\n\n* Age ≥ 18 years\n* Signed informed consent\n* High risk of PaC due to the presence of one of the following risk factors:\n\n  1. Family history of PaC (≥ 2 first-degree or second-degree relatives with PaC in the same family line)\n  2. Confirmed germline mutation of STK11 (LKB1) regardless of family history\n  3. Confirmed germline mutation of CDKN2A leading to the alteration of p16 regardless of family history\n  4. Confirmed germline mutation of APC, ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2 or TP53 AND ≥ 1 first-degree or second-degree relative with PaC\n  5. Present hereditary pancreatitis (recurrent acute pancreatitis or chronic pancreatitis and confirmed germline mutation of PRSS1)\n* Age:\n\n  1. Person with a family history of PaC: \\> 50 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  2. Person with STK11 mutation: \\> 35 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  3. Person with CDKN2A mutation: \\> 40 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  4. Person with APC, ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2 or TP53 mutation: \\> 45 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  5. Person with hereditary pancreatitis: \\> 40 years or 20 years after the 1st attack (whichever comes first)\n\nExclusion Criteria Arm 2:\n\n* Pregnancy of planning to conceive in the next 12 months\n* History of any cancer disease\n* Present incurable malignancy\n* Inability to undergo planned medical imaging or blood sampling\n* Vegan or vegetarian diet",{"count":636,"type":21},419,[24],"Software \"Lipidica\" is intended to be used for processing data generated by the in-house in vitro diagnostic medical device for lipidomic testing for the purpose of screening Pancreatic cancer (PaC) in the population at high risk of this cancer due to familial risk, selected gene mutations or hereditary pancreatic diseases.\n\nThe primary objective is to verify that the investigational IVDSW can discriminate between results of patients with Pancreatic cancer and persons without Pancreatic cancer but at higher risk of this cancer disease due to their predispositions.\n\nParticipants will:\n\n* come to baseline and end of study visit for blood sampling and medical imaging\n* some participant will undertake one more visit depending on their results on baseline",[30,97,640,641],"Hereditary Diseases","Pancreatitis, Chronic","2026-04-22",{"date":577,"type":42},{"date":645,"type":42},"2024-09-10",{"date":647,"type":21},"2027-09-26",{"name":649,"class":262},"Lipidica, a.s.",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":660,"conditions":661,"keywords":662,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":81},"100570291","convertases-and-pancreatic-cancer-cohort-of-patients-treated-for-pancreatic-adenocarcinoma-100570291","NCT06705335","Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma","Convertases and Pancreatic Cancer. New Therapeutic and Prognostic Approach: Cohort of Patients Treated for Pancreatic Adenocarcinoma (CONVERCAP)","CONVERCAP","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Pancreatic adenocarcinoma (suspected on radiological assessment or histologically proven):\n\n   1. Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer.\n   2. Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer.\n3. Whatever the stage of the disease.\n4. Whatever the type of treatment proposed (systemic, surgery, radiotherapy, etc.).\n5. Patient who has never received systemic treatment or advanced radiotherapy.\n6. WHO 0-1-2.\n7. Life expectancy \\> 3 months.\n8. Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).\n9. Patient affiliated to a social security scheme in compliance with Article 1121-11 of the French Public Health Code.\n\nExclusion Criteria:\n\n1. Indication for biopsy for primary diagnosis of pancreatic cancer\n2. No indication for treatment of pancreatic cancer.\n3. Adjuvant\u002Fneoadjuvant chemotherapy completed less than 6 months ago in the case of patients with recurrent disease.\n4. Patient already included in the study.\n5. Geographical, social or psychological factors rendering the patient unable to undergo study monitoring and procedures.",{"count":659,"type":21},50,"This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and\u002For metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.",[30],[663],"Convertases","2026-04-15",{"date":666,"type":42},"2026-04-20",{"date":668,"type":42},"2026-03-27",{"date":670,"type":21},"2029-01",{"name":672,"class":49},"Institut Bergonié"]